---
id: asco-breast-cancer-adjuvant-2024
title: "Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline"
short_title: "ASCO Adjuvant Breast Cancer 2024"

organization: American Society of Clinical Oncology
collaborators: null
country: US
url: https://ascopubs.org/doi/10.1200/JCO.24.00886
doi: 10.1200/JCO.24.00886
pmid: 38768407
open_access: false

specialty: oncology
guideline_type: clinical-practice
evidence_system: other
conditions:
  - breast cancer
  - early breast cancer
  - HER2-negative breast cancer
tags:
  - adjuvant therapy
  - CDK4/6 inhibitors
  - abemaciclib
  - ribociclib
  - chemotherapy

publication_date: 2024-05-20
previous_version_date: 2020-10-05
status: current
supersedes: asco-breast-cancer-adjuvant-2020
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-21
---

## Scope

Recommendations for optimal adjuvant chemotherapy and targeted therapy for early-stage breast cancer, including use of CDK4/6 inhibitors (abemaciclib, ribociclib) in stage II-III disease.

## Notes

Rapid recommendation update addressing 2024 data on adjuvant CDK4/6 inhibitors. Companion clinical insights article available for implementation guidance.
